Retatrutide
1–12 mg · Weekly
Evidence
- Human Studies
- 5
- Animal Studies
- 20
- Clinical Status
- Investigational
- Confidence
- Moderate
- Long-Term Safety
- Established short/medium-term in Phase 2/3 trials; long-term real-world data still accumulating
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors, developed by Eli Lilly and studied in large pharmaceutical clinical trials for obesity and metabolic disease. It is the furthest along in formal human trials of any compound in this list, but was not FDA approved as of this writing — compounded/research versions are not the same as the eventual approved drug product.
Common Protocols
- Weekly subcutaneous injection, titrated up over weeks/months in published trials — self-directed dosing outside a trial or prescription carries real risk of getting this wrong
Side Effects
- GI side effects (nausea, diarrhea, constipation) were the most common in trials
- Trial data comes from a manufactured, quality-controlled product — research-grade/compounded versions carry additional, unstudied risk
Interactions
- Other GLP-1/GIP-class medications should not be combined without clinician guidance
Practical Details
- Cost
- $$$
- Typical Vial Size
- 10 mg
- Storage
- Refrigerate after reconstitution
Research Links
GLP-1/GIP/Glucagon triple agonist